文献速递类风湿关节炎

MRI与超声对早期类风湿关节炎治疗反应及骨侵蚀进展的预测价值

Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy.
PubMed 文献 · RMD Open · 2021-01-01

本研究在218例未使用改善病情抗风湿药的早期类风湿关节炎患者中,采用达标治疗策略,定期进行MRI和超声检查。基线MRI炎症与MRI骨侵蚀进展相关,超声与放射学骨侵蚀进展相关,但无影像学炎症指标与早期甲氨蝶呤失败相关。临床缓解期多数患者仍存在影像学炎症,但影像信息未能改善任何结局的预测模型。

要点

  • 基线MRI炎症预测MRI骨侵蚀进展,超声预测放射学骨侵蚀进展。
  • 无影像学炎症指标与早期甲氨蝶呤失败相关。
  • 临床缓解期多数患者存在影像学炎症,但影像信息未改善预测模型。

核心结论

  • 影像学检测的炎症在诊断时和缓解期均与未来疾病发展的某些方面相关,但对预测模型无显著改善,系统使用MRI和超声在早期RA管理中的价值有限。

研究设计与样本

  • 为期2年的研究,纳入218例未使用改善病情抗风湿药的早期RA患者,接受严格控制的达标治疗策略,定期进行MRI和超声检查。

主要发现

  • 基线MRI炎症与MRI骨侵蚀进展相关,基线超声与放射学骨侵蚀进展相关。
  • 无影像学炎症指标与早期甲氨蝶呤失败相关。
  • 临床缓解期多数患者存在影像学炎症。
  • 腱鞘炎与第二年治疗升级相关,滑膜炎和腱鞘炎与第二年MRI/放射学骨侵蚀进展相关。
  • 影像信息未改善任何结局的预测模型。

临床怎么用

  • 系统使用MRI和超声在早期RA达标治疗管理中的附加价值有限,不应常规依赖影像学炎症指标预测治疗反应或骨侵蚀进展。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate if inflammation detected by MRI or ultrasound at rheumatoid arthritis (RA) onset is predictive of erosive progression or poor response to methotrexate monotherapy, and to investigate if subclinical inflammation in remission is predictive of future treatment escalation or erosive progression. METHODS: In a 2-year study, 218 patients with disease-modifying antirheumatic drug-naïve early RA were treated by a tight-control treat-to-target strategy corresponding to current recommendations. MRI and ultrasound were performed at regular intervals. Baseline imaging-based inflammation measures were analysed as predictors for early methotrexate failure and erosive progression using univariate and multivariate regression adjusted for clinical, laboratory and radiographic measures. In patients in remission after 1 year, imaging measures were analysed as predictors of treatment escalation and erosive progression during the second year. The added value of imaging in prediction models was assessed using receiver operating characteristic analyses. RESULTS: Baseline MRI inflammation was associated with MRI erosive progression and ultrasound with radiographic erosive progression. No imaging inflammation measure was associated with early methotrexate failure. Imaging inflammation was present in a majority of patients in clinical remission. Tenosynovitis was associated with treatment escalation, and synovitis and tenosynovitis with MRI/radiographic erosive progression during the second year. Imaging information did not improve prediction models for any of the outcomes. CONCLUSIONS: Imaging-detected inflammation, both at diagnosis and in remission, is associated with elements of future disease development. However, the lack of a significant effect on prediction models indicates limited value of systematic MRI and ultrasound in management of early RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sundin U, Sundlisater NP, Aga AB, et al. Value of MRI and ultrasound for prediction of therapeutic response and erosive progression in patients with early rheumatoid arthritis managed by an aggressive treat-to-target strategy. RMD Open. 2021. PMID: 33547228. doi:10.1136/rmdopen-2020-001525

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。